• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

16.03.2017

Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 16, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of the Authorized Generic of Minastrin® 24 Fe1 (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S. The Authorized Generic of Minastrin® 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy. This Authorized Generic of Minastrin® 24 Fe adds to Teva’s existing portfolio of more than 50 oral contraceptives. In the U.S., one of every two oral contraceptive prescriptions is fille...
13.03.2017

Teva to Present at the Barclays Global Annual Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Mar. 13, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Barclays Global Healthcare Conference in Miami, Florida.   When: Wednesday, March 15, 2017 at 9:00 AM ET   Who: Eyal Desheh, Gr...
06.03.2017

Teva to Present at the Cowen & Company 37th Annual Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA. When:   Wednesday, March 8, 2017 at 9:20 AM ET   Who: Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development, ...
01.03.2017

Teva Announces Launch of Generic Pristiq® in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pristiq®1 (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the U.S. Desvenlafaxine extended-release tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder. Desvenlafaxine extended-release tablets further enhance Teva’s portfolio of antidepressant products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and hol...
28.02.2017

Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia

JERUSALEM--(BUSINESS WIRE)--Feb. 28, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for SD-809 (deutetrabenazine) for the treatment of tardive dyskinesia (TD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2017. “Teva is committed to advancing new therapeutic options for patients with neurological and movement disorders. There remains a significant unmet medical need in tardive dyskinesia,” said Michael Hayden, M.D., Ph.D., Presi...
15.02.2017

Teva Files 2016 Annual Report on Form 20-F

JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has filed its 2016 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva ...
06.02.2017

Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman

Dr. Sol J. Barer Named Chairman of the Board JERUSALEM--(BUSINESS WIRE)--Feb. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that Dr. Yitzhak Peterburg, who has served as Chairman of the Teva Board of Directors since January 2015, has been appointed Interim President and Chief Executive Officer, effective immediately. This follows the mutual agreement between the Board of Teva and Erez Vigodman that Mr. Vigodman is stepping down. Mr. Vigodman’s service on the Teva Board of Directors has also ended. In accordance with the Israeli Companies Law, Dr. Yitzhak Peterburg has steppe...
02.02.2017

Teva Confirms Generic Victoza® Patent Challenge in the United States

JERUSALEM--(BUSINESS WIRE)--Feb. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the U.S. Victoza® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on available information, Teva believes it is a "first applicant" to file an ANDA for the generic version of Victoza®; should its ANDA be approved, Teva...
01.02.2017

Teva to Report Fourth Quarter 2016 Financial Results on February 13, 2017

JERUSALEM--(BUSINESS WIRE)--Feb. 1, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter 2016 financial results on Monday, February 13, 2017 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its fourth quarter 2016 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Canada 1-866-992-6802 or Internation...